An Update on Repurposed Medications for the Treatment of Drug-Resistant Tuberculosis.

An Update on Repurposed Medications for the Treatment of Drug-Resistant Tuberculosis.

Expert Rev Clin Pharmacol. 2016 Jul 4;

Authors: Mafukidze A, Harausz E, Furin J

Abstract
INTRODUCTION: Drug-resistant forms of tuberculosis are a major public health problem with a serious global impact. Although there have recently been two new drugs introduced for the treatment of drug-resistant TB (bedaquiline and delamanid), the current therapeutic armamentarium is limited. Because treatment of drug-resistant TB requires the use of a multidrug-regimen, there has been growing interest in the use of antibiotics developed for other infectious pathogens but that have shown efficacy in the treatment of TB.
AREAS COVERED: This paper will review these "re-purposed" agents-including the beta-lactams, clarithromycin, clofazimine, the fluoroquinolones, and linezolid-with a focus on their efficacy, safety, and pharmacokinetic properties.

PMID: 27376490 [PubMed - as supplied by publisher]